healthneutral
Bile Duct Cancer: Why Korea Stands Out
Republic of KoreaWednesday, March 5, 2025
But it's not just about these infections. The genetic makeup of BTC in Korean patients is different from what's seen in other parts of the world. For example, Korean patients with ICC have lower rates of IDH1 mutations and FGFR2 fusions. On the other hand, GBC patients in Korea have a higher rate of ERBB2 amplification.
These genetic differences matter because they can affect how the cancer responds to treatment. In Korea, two drugs, ivosidenib and pemigatinib, have been approved for BTC patients with specific genetic mutations.
Understanding these unique features of BTC in Korea can help guide future research and improve treatment options. By comparing Korean data with global data, researchers can gain insights into the disease's behavior and develop more effective therapies.
It's also important to note that BTC is not just a Korean problem. It affects people worldwide, and understanding its unique features in different regions can help in the global fight against this disease.
Actions
flag content